QCLS insider buying and SEC filings, explained
TNF Pharmaceuticals, Inc. · CIK 1321834
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Mar 30, 2026 | Purchase (code P) | Chelsea Sierra Voss (Director) bought 1,753 shares indirectly (by retirement or benefit plan) at $3.15 ($6K), reported as a purchase (code P). Holdings by retirement or benefit plan up 3% to 61,555 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 14, 2026 |
| Sep 4–Nov 14, 2025 | Other purchase | PharmaCyte Biotech, Inc. (10% owner) bought 1,779,730 shares in 2 share classes; the filing does not report a price. New position of 889,865 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 18, 2025 |
14 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow QCLS in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.